SK284711B6 - Farmaceutická kompozícia s protinádorovým účinkom na báze karboplatiny - Google Patents
Farmaceutická kompozícia s protinádorovým účinkom na báze karboplatiny Download PDFInfo
- Publication number
- SK284711B6 SK284711B6 SK209-2001A SK2092001A SK284711B6 SK 284711 B6 SK284711 B6 SK 284711B6 SK 2092001 A SK2092001 A SK 2092001A SK 284711 B6 SK284711 B6 SK 284711B6
- Authority
- SK
- Slovakia
- Prior art keywords
- carboplatin
- pharmaceutical composition
- weight
- cyclobutanedicarboxylic acid
- impurities
- Prior art date
Links
- 229960004562 carboplatin Drugs 0.000 title claims abstract description 107
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 4
- 190000008236 carboplatin Chemical compound 0.000 title 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims abstract description 105
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000007864 aqueous solution Substances 0.000 claims abstract description 19
- 239000012535 impurity Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000003446 ligand Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 150000007942 carboxylates Chemical group 0.000 claims abstract description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000000354 decomposition reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000011194 good manufacturing practice Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000008297 liquid dosage form Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- -1 carboplatin carboxylate Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940041769 carboplatin 10 mg/ml Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0091—Complexes with metal-heteroatom-bonds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ19982588A CZ292170B6 (cs) | 1998-08-14 | 1998-08-14 | Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny |
| PCT/CZ1999/000028 WO2000009097A2 (en) | 1998-08-14 | 1999-08-10 | Pharmaceutical composition with antitumor activity on the basis of carboplatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK2092001A3 SK2092001A3 (en) | 2001-07-10 |
| SK284711B6 true SK284711B6 (sk) | 2005-09-08 |
Family
ID=5465233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK209-2001A SK284711B6 (sk) | 1998-08-14 | 1999-08-10 | Farmaceutická kompozícia s protinádorovým účinkom na báze karboplatiny |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6589988B1 (cs) |
| EP (1) | EP1107750B1 (cs) |
| AT (1) | ATE281832T1 (cs) |
| AU (1) | AU5024599A (cs) |
| BG (1) | BG105207A (cs) |
| CZ (1) | CZ292170B6 (cs) |
| DE (1) | DE69921832T2 (cs) |
| ES (1) | ES2229737T3 (cs) |
| HR (1) | HRP20010110B1 (cs) |
| HU (1) | HUP0104304A3 (cs) |
| NO (1) | NO20010507D0 (cs) |
| PL (1) | PL346363A1 (cs) |
| PT (1) | PT1107750E (cs) |
| RU (1) | RU2188640C1 (cs) |
| SK (1) | SK284711B6 (cs) |
| UA (1) | UA73281C2 (cs) |
| WO (1) | WO2000009097A2 (cs) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2267255T3 (es) | 1998-04-03 | 2007-03-01 | Ajinomoto Co., Inc. | Agentes antitumorales. |
| DE602005014393D1 (de) * | 2005-03-28 | 2009-06-18 | Dabur Pharma Ltd | Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln |
| KR101127159B1 (ko) * | 2009-11-02 | 2012-03-20 | 한국생명공학연구원 | 식물병원성 그람음성 세균의 분비체계를 저해하는 카보프라틴 화합물을 유효성분으로 함유하는 식물병 방제제 |
| ES3014002T3 (en) * | 2018-08-31 | 2025-04-16 | Sun Pharmaceutical Ind Ltd | Parenteral dosage form of carboplatin |
| US12427104B1 (en) | 2025-04-01 | 2025-09-30 | Ingenus Pharmaceuticals, Llc | Injectable carboplatin formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS269719B1 (en) * | 1986-12-29 | 1990-05-14 | Kiss Frantisek | Platinum cytostatic |
| JPH01146826A (ja) * | 1987-12-03 | 1989-06-08 | Nippon Kayaku Co Ltd | 白金化合物の凍結乾燥製剤 |
| NL8901433A (nl) * | 1989-06-06 | 1991-01-02 | Pharmachemie Bv | Carboplatinpreparaat. |
| US5455270A (en) * | 1993-08-11 | 1995-10-03 | Bristol-Myers Squibb Co. | Stabilized solutions of platinum(II) antitumor agents |
| ES2160117T3 (es) * | 1994-02-07 | 2001-11-01 | Pliva Pharmaceutical Industry | Composicion farmaceutica antitumoral a base de carboplatino, y su procedimiento de produccion. |
-
1998
- 1998-08-14 CZ CZ19982588A patent/CZ292170B6/cs not_active IP Right Cessation
-
1999
- 1999-08-10 US US09/762,458 patent/US6589988B1/en not_active Expired - Fee Related
- 1999-08-10 PT PT99934452T patent/PT1107750E/pt unknown
- 1999-08-10 ES ES99934452T patent/ES2229737T3/es not_active Expired - Lifetime
- 1999-08-10 HU HU0104304A patent/HUP0104304A3/hu unknown
- 1999-08-10 SK SK209-2001A patent/SK284711B6/sk not_active IP Right Cessation
- 1999-08-10 PL PL99346363A patent/PL346363A1/xx not_active IP Right Cessation
- 1999-08-10 AT AT99934452T patent/ATE281832T1/de not_active IP Right Cessation
- 1999-08-10 DE DE69921832T patent/DE69921832T2/de not_active Expired - Lifetime
- 1999-08-10 WO PCT/CZ1999/000028 patent/WO2000009097A2/en not_active Ceased
- 1999-08-10 EP EP99934452A patent/EP1107750B1/en not_active Expired - Lifetime
- 1999-08-10 RU RU2001104352/14A patent/RU2188640C1/ru not_active IP Right Cessation
- 1999-08-10 HR HR20010110A patent/HRP20010110B1/xx not_active IP Right Cessation
- 1999-08-10 AU AU50245/99A patent/AU5024599A/en not_active Abandoned
- 1999-10-08 UA UA2001021022A patent/UA73281C2/uk unknown
-
2001
- 2001-01-30 NO NO20010507A patent/NO20010507D0/no not_active Application Discontinuation
- 2001-01-31 BG BG105207A patent/BG105207A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0104304A3 (en) | 2004-04-28 |
| ES2229737T3 (es) | 2005-04-16 |
| WO2000009097A3 (en) | 2000-05-18 |
| ATE281832T1 (de) | 2004-11-15 |
| UA73281C2 (en) | 2005-07-15 |
| US6589988B1 (en) | 2003-07-08 |
| HUP0104304A2 (hu) | 2002-03-28 |
| SK2092001A3 (en) | 2001-07-10 |
| DE69921832D1 (de) | 2004-12-16 |
| DE69921832T2 (de) | 2005-11-03 |
| EP1107750A2 (en) | 2001-06-20 |
| PT1107750E (pt) | 2005-02-28 |
| HRP20010110A2 (en) | 2002-02-28 |
| HRP20010110B1 (en) | 2005-10-31 |
| BG105207A (en) | 2001-07-31 |
| WO2000009097A2 (en) | 2000-02-24 |
| EP1107750B1 (en) | 2004-11-10 |
| RU2188640C1 (ru) | 2002-09-10 |
| PL346363A1 (en) | 2002-02-11 |
| CZ292170B6 (cs) | 2003-08-13 |
| NO20010507L (no) | 2001-01-30 |
| CZ258898A3 (cs) | 2000-02-16 |
| AU5024599A (en) | 2000-03-06 |
| NO20010507D0 (no) | 2001-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002216042B2 (en) | Freeze-dried pantoprazole preparation and pantoprazole injection | |
| JP3629044B2 (ja) | 白金（ｉｉ）抗腫瘍剤の安定化溶液 | |
| US4889724A (en) | Stable aqueous cisplatin solutions | |
| RU2519764C1 (ru) | Стабильная готовая к применению композиция парацетамола для инъекций | |
| ZA200206688B (en) | Esmolol formulation. | |
| CZ298581B6 (cs) | Farmaceuticky stabilní prípravek oxaliplatiny k parenterální aplikaci | |
| SK284711B6 (sk) | Farmaceutická kompozícia s protinádorovým účinkom na báze karboplatiny | |
| AU2004314154B2 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| DK2277546T3 (en) | Stable, ready to use, injectable paracetamol formulation | |
| KR100364466B1 (ko) | 주사용메스나용액,이의제조방법및이를함유하는약제 | |
| WO1994025032A1 (fr) | Injection stabilisee et procede de stabilisation d'injection | |
| RU2313346C2 (ru) | Фармацевтическая композиция | |
| EP4422692A1 (en) | Phytonadione for parenteral administration | |
| EP0369714A1 (en) | Cisplatin hypertonic solution | |
| JP2025511651A (ja) | ペメトレキセド二ナトリウム液体組成物、その製造方法及び応用 | |
| CZ228896A3 (cs) | Protinádorový léčebný přípravek na bázi karboplatiny a způsob jeho výroby | |
| BR102014005885B1 (pt) | Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso | |
| SK280192B6 (sk) | Protinádorový liečivý prípravok carboplatiny a spô | |
| HK1036012A1 (en) | Stable mitoxantron solutions | |
| HK1036012B (en) | Stable mitoxantron solutions | |
| JPH05262644A (ja) | アミノ酸含有輸液の安定化方法 | |
| HK1081451B (en) | Medicinal composition | |
| CA2762348A1 (en) | Stabilized and lyophilized formulation of anthracycline compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20100810 |